Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.7012
+0.03905.89%
Post-market: 0.70690.0057+0.82%19:59 EDT
Volume:5.92M
Turnover:4.17M
Market Cap:194.93M
PE:-1.41
High:0.7300
Open:0.6630
Low:0.6601
Close:0.6622
52wk High:2.55
52wk Low:0.5261
Shares:278.00M
Float Shares:245.00M
Volume Ratio:0.58
T/O Rate:2.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4975
EPS(LYR):-0.2582
ROE:-547.87%
ROA:-49.87%
PB:6.24
PE(LYR):-2.72

Loading ...

Humacyte sets first-quarter results webcast and conference call

Reuters
·
May 08

Humacyte to Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

THOMSON REUTERS
·
May 08

Humacyte (HUMA) Motion to Dismiss Ruling Keeps Key Securities Claims Alive

TIPRANKS
·
May 05

Humacyte (HUMA) Gets a Buy from Barclays

TIPRANKS
·
Apr 29

Humacyte Price Target Maintained With a $3.00/Share by BTIG

Dow Jones
·
Apr 28

Humacyte hosts virtual KOL event on ATEV for dialysis AV access

Reuters
·
Apr 27

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 24

Humacyte Inc - Enters Third Amendment to Distribution Agreement With Fresenius on April 21, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 24

Humacyte Inc - Gains Sole Worldwide Rights to Distribution Product - SEC Filing

THOMSON REUTERS
·
Apr 24

Humacyte Inc - to Pay Fresenius Mid-Single to Low Double Digit Royalties on U.S. Sales - SEC Filing

THOMSON REUTERS
·
Apr 24

Humacyte regains exclusive ex-U.S. Symvess distribution rights from Fresenius Medical Care

Reuters
·
Apr 24

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

THOMSON REUTERS
·
Apr 24

Humacyte Inc - U.S. Distribution Terms for Symvess Remain Unchanged

THOMSON REUTERS
·
Apr 24

Humacyte Inc - Gains Exclusive Ex-U.S. Distribution Rights to Symvess; Fresenius to Receive Low-Single-Digit Royalties on Net Sales

THOMSON REUTERS
·
Apr 24

Humacyte names Jim Mercadante chief commercial officer

Reuters
·
Apr 22

Press Release: Humacyte Appoints Jim Mercadante as Chief Commercial Officer

Dow Jones
·
Apr 22

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 21

Humacyte Says Israeli Health Ministry Accepts Marketing Authorization Application for Symvess

MT Newswires Live
·
Apr 21

Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair

THOMSON REUTERS
·
Apr 21

Humacyte: Ministry of Health Has Set 180-Working-Day Review Period for Maa Due to Existing FDA Approval of Symvess in Extremity Vascular Trauma

THOMSON REUTERS
·
Apr 21